Commodore Capital LP bought a new position in shares of Athira Pharma, Inc. (NASDAQ:ATHA – Free Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 464,398 shares of the company’s stock, valued at approximately $3,515,000. Commodore Capital LP owned 0.12% of Athira Pharma as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Focus Partners Wealth bought a new position in shares of Athira Pharma during the third quarter worth about $35,000. Jane Street Group LLC acquired a new stake in Athira Pharma during the 4th quarter valued at approximately $100,000. Renaissance Technologies LLC boosted its stake in shares of Athira Pharma by 44.7% in the 4th quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock valued at $569,000 after purchasing an additional 23,223 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of Athira Pharma during the fourth quarter worth $2,891,000. Finally, Spruce Street Capital LP bought a new position in Athira Pharma during the fourth quarter worth $2,980,000. 57.12% of the stock is owned by institutional investors and hedge funds.
Athira Pharma Trading Down 4.5%
Shares of ATHA opened at $8.22 on Thursday. The firm’s fifty day simple moving average is $9.39 and its two-hundred day simple moving average is $7.42. Athira Pharma, Inc. has a 12 month low of $0.23 and a 12 month high of $8.36. The stock has a market capitalization of $32.42 million, a P/E ratio of -0.85 and a beta of 2.79.
Athira Pharma Company Profile
Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).
The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.
See Also
- Five stocks we like better than Athira Pharma
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding ATHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athira Pharma, Inc. (NASDAQ:ATHA – Free Report).
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
